Erratum: Glioblastoma multiforme recurrence: An exploratory study of 18F FPPRGD 2 PET/CT (Radiology (2015) 277:2 (497-506) DOI: 10.1148/radiol.2015141550);Glioblastoma multiforme recurrence: An exploratory study of 18 F FPPRGD 2 PET/CT

Radiology

Volumn 277, Issue 2, 2015, Pages 497-506

  Iagaru, Andrei ^a   Mosci, Camila ^a   Mittra, Erik ^a   Zaharchuk, Greg ^a   Fischbein, Nancy ^a   Harsh, Griffith ^b   Li, Gordon ^b   Nagpal, Seema ^b   Recht, Lawrence ^b   Gambhir, Sanjiv Sam ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID 2 FLUOROPROPIONYL F 18; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE MEGLUMINE; MACROGOL; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; CYCLOPEPTIDE; FLUORINE; FPP(RGD)2;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BRAIN SURGERY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ELECTROCARDIOGRAPHY; EXPLORATORY RESEARCH; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATIENT SAFETY; PET SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; VITAL SIGN; BRAIN TUMOR; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; SYNTHESIS; TUMOR RECURRENCE;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84946049099     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016164020     Document Type: Erratum

References (22)

1. Leite de Oliveira R, Hamm A, Mazzone M. Growing tumor vessels: more than one way to skin a cat-implications for angiogenesis targeted cancer therapies. Mol Aspects Med 2011;32(2):71-87.
2. Sun X, Yan Y, Liu S, et al. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 2011;52(1):140-146.
3. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J 2000;6(Suppl 3):S245-S249.
4. Kerr JS, Slee AM, Mousa SA. The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs 2002;11(12):1765-1774.
5. Gilbert MR, Kuhn J, Lamborn KR, et al. Ci-lengitide in patients with recurrent glioblas-toma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 2012;106(1):147-153.
6. Soffetti R, Trevisan E, Rudà R. What have we learned from trials on antiangiogenic agents in glioblastoma? Expert Rev Neu-rother 2014;14(1):1-3.
7. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10(13):1439-1455.
8. Lim M, Guccione S, Haddix T, et al. a(v) b(3) Integrin in central nervous system tumors. Hum Pathol 2005;36(6):665-669.
9. Moen MD. Bevacizumab: in previously treated glioblastoma. Drugs 2010;70(2):181-189.
10. Mittra ES, Goris ML, Iagaru AH, et al. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceu-tical agent for imaging a(v)b(3) integrin levels. Radiology 2011;260(1):182-191.
11. Iagaru A, Mosci C, Shen B, et al. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology 2014; 273(2):549-559.
12. Chin FT, Shen B, Liu S, et al. First experience with clinical-grade ([18F]FPP(RGD2): an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol 2012; 14(1):88-95.
13. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47(5):885-895.
14. Nordhausen K, Oja RL. Multivariate L1 statistical methods: the package MNM. J Stat Softw 2011;43(5):1-28.
15. Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med 2011;52(2):311-317.
16. McParland BJ, Miller MP, Spinks TJ, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med 2008;49(10): 1664-1667.
17. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008;49(6):879-886.
18. Tomasi G, Kenny L, Mauri F, Turkheimer F, Aboagye EO. Quantifcation of recep-tor-ligand binding with [8F]fuciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging 2011;38(12):2186-2197.
19. Doss M, Kolb HC, Zhang JJ, et al. Biodis-tribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med 2012;53(5):787-795.
20. Wan W, Guo N, Pan D, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofu-orination. J Nucl Med 2013;54(5):691-698.
21. Liu Z, Liu S, Wang F, Liu S, Chen X. Non-invasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging 2009;36(8):1296-1307.
22. Wu Z, Li ZB, Cai W, et al. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphav-beta3 integrin expression. Eur J Nucl Med Mol Imaging 2007;34(11):1823-1831.